Clinical reference Biomarker Directory
Back to directory

Beta-Glucuronidase

Emerging

Beta-glucuronidase (GUSB) deficiency causes Sly syndrome (MPS VII), now treatable with a 2017 FDA-approved enzyme replacement therapy.

Also known as GUSB beta-glucuronidase Sly syndrome enzyme
In plain language

This enzyme breaks down certain complex sugars in cells. Without it, a rare and serious inherited condition called Sly syndrome develops. A specific enzyme replacement drug was approved in 2017, giving patients a real treatment option that simply didn't exist before.

Biomarker & context

Beta-glucuronidase, encoded by the GUSB gene, is a lysosomal enzyme required to break down glycosaminoglycans; its deficiency causes mucopolysaccharidosis type VII (MPS VII, Sly syndrome).

What it indicates

Deficient enzyme activity confirms MPS VII, a rare, severe multisystem lysosomal storage disorder causing skeletal abnormalities, organ enlargement, and in severe cases, hydrops fetalis (fluid accumulation before birth).

Diagnosis & clinical testing

Diagnosed via enzyme activity assay in leukocytes or fibroblasts, with GUSB gene sequencing confirming the diagnosis and informing prognosis, since disease severity varies based on the specific mutations involved.

Guiding treatment

Vestronidase alfa, an enzyme replacement therapy, was FDA-approved in 2017 specifically for MPS VII, giving patients a treatment option that didn't exist for most of medical history, similar in concept to the enzyme replacement therapies discussed for other lysosomal storage disorders (Fabry, Hunter syndrome) earlier in this biomarker set.

Clinical significance

Follows the same enzyme replacement therapy model as other lysosomal storage disorders discussed in this biomarker set.

References
  1. FDA. (2017). Vestronidase Alfa (Mepsevii) Approval for Mucopolysaccharidosis VII.